These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 28623073)

  • 1. Commentary on "Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer". Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Eur Urol. Jun 2016;69(6):992-5.
    Freedland S; Aronson W
    Urol Oncol; 2017 Aug; 35(8):536. PubMed ID: 28623073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.
    Cheng HH; Pritchard CC; Boyd T; Nelson PS; Montgomery B
    Eur Urol; 2016 Jun; 69(6):992-5. PubMed ID: 26724258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commentary on: "Inherited DNA-repair gene mutations in men with metastatic prostate cancer." Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016 Aug 4;375(5):443-53.
    Lee BH
    Urol Oncol; 2017 Sep; 35(9):575-576. PubMed ID: 28789927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
    Slootbeek PHJ; Duizer ML; van der Doelen MJ; Kloots ISH; Kuppen MCP; Westgeest HM; Uyl-de Groot CA; Pamidimarri Naga S; Ligtenberg MJL; van Oort IM; Gerritsen WR; Schalken JA; Kroeze LI; Bloemendal HJ; Mehra N
    Int J Cancer; 2021 Jan; 148(2):385-395. PubMed ID: 32965028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Commentary on "Inherited DNA-repair gene mutations in men with metastatic prostate cancer". Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016;375(5):443-53.
    Freedland SJ; Aronson WJ
    Urol Oncol; 2017 Aug; 35(8):536-537. PubMed ID: 28623070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
    Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
    Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-Gene Next-Generation Sequencing Panel for Analysis of
    Maloberti T; De Leo A; Coluccelli S; Sanza V; Gruppioni E; Altimari A; Zagnoni S; Giunchi F; Vasuri F; Fiorentino M; Mollica V; Ferrari S; Miccoli S; Visani M; Turchetti D; Massari F; Tallini G; de Biase D
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.
    Taylor RA; Fraser M; Livingstone J; Espiritu SM; Thorne H; Huang V; Lo W; Shiah YJ; Yamaguchi TN; Sliwinski A; Horsburgh S; Meng A; Heisler LE; Yu N; Yousif F; Papargiris M; Lawrence MG; Timms L; Murphy DG; Frydenberg M; Hopkins JF; Bolton D; Clouston D; McPherson JD; van der Kwast T; Boutros PC; Risbridger GP; Bristow RG
    Nat Commun; 2017 Jan; 8():13671. PubMed ID: 28067867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation.
    Kosaka T; Hongo H; Aimono E; Matsumoto K; Hayashida T; Mikami S; Nishihara H; Oya M
    Pathol Int; 2019 Dec; 69(12):715-720. PubMed ID: 31631483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commentary on "Integrative clinical genomics of advanced prostate cancer". Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.Cell. 21 May 2015;161(5):1215-1228.
    Freedland SJ; Aronson WJ
    Urol Oncol; 2017 Aug; 35(8):535. PubMed ID: 28623072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing.
    Nogueira Costa I; Reis J; Meireles S; Ribeiro MJ; Barbosa M; Augusto I
    Eur J Case Rep Intern Med; 2022; 9(5):003331. PubMed ID: 35774732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diverse
    Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
    Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
    [No Abstract]   [Full Text] [Related]  

  • 13. Germline BLM mutations and metastatic prostate cancer.
    Ledet EM; Antonarakis ES; Isaacs WB; Lotan TL; Pritchard C; Sartor AO
    Prostate; 2020 Feb; 80(2):235-237. PubMed ID: 31816118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Lysis Syndrome After Platinum-based Chemotherapy in Castration-resistant Prostate Cancer With a BRCA2 Mutation: A Case Report.
    Gongora ABL; Canedo FSNA; de Melo ALA; Bezerra ROF; Asprino PF; Camargo AA; Bastos DA
    Clin Genitourin Cancer; 2019 Feb; 17(1):e61-e64. PubMed ID: 30270052
    [No Abstract]   [Full Text] [Related]  

  • 15. Germline Mutations in DNA Repair Genes in Patients With Metastatic Castration-resistant Prostate Cancer.
    Holeckova K; Baluchova K; Hives M; Musak L; Kliment J; Skerenova M
    In Vivo; 2020; 34(4):1773-1778. PubMed ID: 32606146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors.
    Decker B; Karyadi DM; Davis BW; Karlins E; Tillmans LS; Stanford JL; Thibodeau SN; Ostrander EA
    Am J Hum Genet; 2016 May; 98(5):818-829. PubMed ID: 27087322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of
    Chakraborty G; Armenia J; Mazzu YZ; Nandakumar S; Stopsack KH; Atiq MO; Komura K; Jehane L; Hirani R; Chadalavada K; Yoshikawa Y; Khan NA; Chen Y; Abida W; Mucci LA; Lee GM; Nanjangud GJ; Kantoff PW
    Clin Cancer Res; 2020 Apr; 26(8):2047-2064. PubMed ID: 31796516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer.
    Hart SN; Ellingson MS; Schahl K; Vedell PT; Carlson RE; Sinnwell JP; Barman P; Sicotte H; Eckel-Passow JE; Wang L; Kalari KR; Qin R; Kruisselbrink TM; Jimenez RE; Bryce AH; Tan W; Weinshilboum R; Wang L; Kohli M
    BMJ Open; 2016 Apr; 6(4):e010332. PubMed ID: 27084275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA repair defects in prostate cancer: impact for screening, prognostication and treatment.
    Warner EW; Yip SM; Chi KN; Wyatt AW
    BJU Int; 2019 May; 123(5):769-776. PubMed ID: 30281887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel germline BRCA2 mutation in a Chinese patient with prostate cancer sensitive to platinum chemotherapy: a case report.
    Jiang L; Bai Z; Zhu S; Zhao T; Yang Y; Li Z; Chen D; Wu Z; Wang Y; Zhou F; Li Y
    BMC Urol; 2021 Aug; 21(1):114. PubMed ID: 34425813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.